The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes (PROs) in the C-POST trial of adjuvant cemiplimab (cemi) vs placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC).
 
Annette Lim
Research Funding - Regeneron
(OPTIONAL) Uncompensated Relationships - Lilly
 
Sandro Porceddu
Leadership - Icon Cancer Care
Consulting or Advisory Role - Regeneron
Patents, Royalties, Other Intellectual Property - UpToDate
 
Fiona Day
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Varian Medical Systems
Travel, Accommodations, Expenses - Merck
 
Vishal Patel
Honoraria - Almirall; Regeneron; Sun Pharma
Consulting or Advisory Role - Almirall; Regeneron; Sun Pharma
Speakers' Bureau - Almirall; Regeneron; Sun Pharma
Research Funding - Regeneron
 
Joanna Walker
Research Funding - Regeneron
 
Maite Schurmann
No Relationships to Disclose
 
Paola Queirolo
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pierre Fabre; Roche/Genentech; Sanofi; Sun Pharma Advanced Research Company
Travel, Accommodations, Expenses - MSD Oncology; Sanofi/Regeneron
 
Javier Cañueto
Honoraria - Almirall; Kyowa Kirin; Novartis; Regeneron; Sanofi; Sun Pharma; Takeda
Consulting or Advisory Role - Almirall; Kyowa Kirin; Regeneron; Takeda
Speakers' Bureau - Almirall; Kyowa Kirin; Novartis; Regeneron; Sanofi; Sun Pharma; Takeda
Research Funding - Castle Biosciences; Sanofi/Regeneron
Expert Testimony - Almirall; Regeneron
Travel, Accommodations, Expenses - Almirall; Castle Biosciences; Novartis; Regeneron; Sanofi
 
Flavio Augusto Ferreira da Silva
No Relationships to Disclose
 
Alexander Stratigos
Honoraria - Abbvie; Genesis Pharma; Leo Pharma; UCB
Consulting or Advisory Role - Regeneron
Research Funding - Regeneron (Inst); Sanofi (Inst)
 
Alexander Guminski
Consulting or Advisory Role - Astellas Pharma; BMS GmbH & Co. KG
Research Funding - Sun Pharma
Travel, Accommodations, Expenses - Sun Pharma
Other Relationship - Regeneron
 
Shikha Bansal
No Relationships to Disclose
 
Camryn Joseph
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Priscila Goncalves
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - I am an inventor on 2 patents, as a REGENERON employee - PCT publication 2023/133280 - PCT publication 2023/17772
 
Matthew Fury
Employment - Regeneron; Regeneron (I)
Stock and Other Ownership Interests - Regeneron; Regeneron (I)
Research Funding - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneorn; Regeneron (I)
 
Suk-Young Yoo
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Chieh-I Chen
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
James Harnett
Employment - Regeneron
Stock and Other Ownership Interests - Pfizer; Regeneron
 
Lei Chi
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Danny Rischin
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Decibel Therapeutics (Inst); Erasca, Inc (Inst); Merck (Inst); Regeneron (Inst)
(OPTIONAL) Uncompensated Relationships - Eisai; GlaxoSmithKline; Merck; Regeneron